Suchergebnisse - "Best, Jennie H"

PubPharm (37)

21

Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly

enthalten in: Journal of diabetes | 2015

von Paul, S. | Maggs, D. | Klein, K. | +1

22

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes : a retrospective observational study

enthalten in: Cardiovascular diabetology | 2015

von Paul, S. | Klein, K. | Maggs, D. | +1

23

Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine

enthalten in: The Annals of pharmacotherapy | 2014

von Pawaskar, M. | Tuttle, K. | Li, Q. | +2

24

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine : achievement of glycemic and cardiovascular goals

enthalten in: Cardiovascular diabetology | 2013

von Meloni, A. | DeYoung, M. | Han, J. | +2

25

Development and validation of the self-management profile for type 2 diabetes (SMP-T2D)

enthalten in: Health and quality of life outcomes | 2012

von Peyrot, M. | Bushnell, D. | Best, J. | +3

26

Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens

enthalten in: The American journal of managed care | 2012

von Best, J. | Romley, J. | Goldman, D. | +2

27

Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States : results from a retrospective claims database analysis

enthalten in: Journal of medical economics | 2012

von Pelletier, E. | Pawaskar, M. | Smith, P. | +2

28

Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States

enthalten in: Journal of medical economics | 2012

von Guillermin, A. | Lloyd, A. | Best, J. | +3

29

Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US

enthalten in: Journal of medical economics | 2012

von Samyshkin, Y. | Guillermin, A. | Best, J. | +2

30

Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment

enthalten in: Diabetes care | 2011

von Best, J. | Rubin, R. | Peyrot, M. | +4